Fourth Annual Program Review Symposium on Phase I and II in Clinical Trials, Tokyo, Japan, June 5-6, 1978. US Japan Agreement on Cancer Research Herausgegeben von Carter, S.K.; Sakurai, Y.
Fourth Annual Program Review Symposium on Phase I and II in Clinical Trials, Tokyo, Japan, June 5-6, 1978. US Japan Agreement on Cancer Research Herausgegeben von Carter, S.K.; Sakurai, Y.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Herstellerkennzeichnung
Die Herstellerinformationen sind derzeit nicht verfügbar.
Inhaltsangabe
of U.S.-Japan Joint Meeting on Phase I and II Clinical Trials.- The New NCI Screen and Its Implications for Clinical Evaluation.- The National Cancer Institute's Natural Products Antineoplastic Development Program.- Methodology of Phase I Study in Japan.- Methodology of Phase II Clinical Trial in Cancer.- Phase II Study of Antineoplastic Agents in Japan.- Clinical Strategy for Evaluation of Anthracycline Analogues.- Preliminary Clinical Study of Aclacinomycin A.- Preclinical and Clinical Studies on Chlorozotocin, a New Nitrosourea with Decreased Bone Marrow Toxicity.- Continuation of Phase II Study of 1-(4-Amino-2-Methylpyrimidine-5-yl)-Methyl-3-(2-Chloroethyl)-3-Nitrosourea Hydrochloride (ACNU).- Review of Experimental Studies on Nitrosourea Derivates in Japan.- The Clinical Evaluation of Analogues, IV. Nitrosoureas.- Review of a New Antimetabolic Agent, 1-Hexylcarbamoyl-5-Fluorouracil (HCFU).- Review of a New Antimetabolic Agent, 1,1-Bis(Tetrahydro-2-Furanyl)-5-Fluoro-2,4-Pyrimidinedione (FD-1).- Effect and Mode of Action of N4-Behenoyl-?-D-Arabinofuranosylcytosine.- Strategy for Evaluation of a New Antitumor Agent in the Treatment of Breast Cancer.- Current Status of Breast Cancer Chemotherapy in Japan.- Present Status of Lung Cancer Chemotherapy in Japan.- Clinical Strategies in the Chemotherapy of Gastrointestinal Cancer.- Clinical Evaluation Strategy in Specific Disease Types - Clinical Study of Gastrointestinal Cancer Chemotherapy in One Institute of Japan.- A Review of Therapeutic Strategies for Phase I-II Trials in Genitourinary Cancer.- Recent Results of Using a Sequential Combination of Bleomycin and Mitomycin C in the Treatment of Metastatic Cervical Cancer.- Pharmacologic and Clinical Studies of N4-Behenoyl-1-Beta-D-Arabinofuranosylcytosine.
of U.S.-Japan Joint Meeting on Phase I and II Clinical Trials.- The New NCI Screen and Its Implications for Clinical Evaluation.- The National Cancer Institute's Natural Products Antineoplastic Development Program.- Methodology of Phase I Study in Japan.- Methodology of Phase II Clinical Trial in Cancer.- Phase II Study of Antineoplastic Agents in Japan.- Clinical Strategy for Evaluation of Anthracycline Analogues.- Preliminary Clinical Study of Aclacinomycin A.- Preclinical and Clinical Studies on Chlorozotocin, a New Nitrosourea with Decreased Bone Marrow Toxicity.- Continuation of Phase II Study of 1-(4-Amino-2-Methylpyrimidine-5-yl)-Methyl-3-(2-Chloroethyl)-3-Nitrosourea Hydrochloride (ACNU).- Review of Experimental Studies on Nitrosourea Derivates in Japan.- The Clinical Evaluation of Analogues, IV. Nitrosoureas.- Review of a New Antimetabolic Agent, 1-Hexylcarbamoyl-5-Fluorouracil (HCFU).- Review of a New Antimetabolic Agent, 1,1-Bis(Tetrahydro-2-Furanyl)-5-Fluoro-2,4-Pyrimidinedione (FD-1).- Effect and Mode of Action of N4-Behenoyl-?-D-Arabinofuranosylcytosine.- Strategy for Evaluation of a New Antitumor Agent in the Treatment of Breast Cancer.- Current Status of Breast Cancer Chemotherapy in Japan.- Present Status of Lung Cancer Chemotherapy in Japan.- Clinical Strategies in the Chemotherapy of Gastrointestinal Cancer.- Clinical Evaluation Strategy in Specific Disease Types - Clinical Study of Gastrointestinal Cancer Chemotherapy in One Institute of Japan.- A Review of Therapeutic Strategies for Phase I-II Trials in Genitourinary Cancer.- Recent Results of Using a Sequential Combination of Bleomycin and Mitomycin C in the Treatment of Metastatic Cervical Cancer.- Pharmacologic and Clinical Studies of N4-Behenoyl-1-Beta-D-Arabinofuranosylcytosine.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826
